Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/EJE-06-0693
European Journal of Endocrinology, Vol 156, Issue 3, 291-293
Copyright © 2007 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Eijk, I C
Right arrow Articles by Simsek, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Eijk, I C
Right arrow Articles by Simsek, S
CASE REPORT

Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis

I C van Eijk1, M J L Peters1,2, M T Nurmohamed1,2,3, A W van Deutekom4, B A C Dijkmans1,2 and S Simsek4

1 Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands, 2 Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands, 3 Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands and 4 Department of Endocrinology/Diabetes Center, VU University Medical Center, PO Box 7057, 1007 MB, Boelelaan 1117, Amsterdam, The Netherlands

(Correspondence should be addressed to S Simsek; Email: Simsek{at}vumc.nl)

Abstract

Tumour necrosis factor {alpha} (TNF{alpha}) is a pro-inflammatory cytokine which has been closely linked to obesity and insulin resistance. We present two cases of patients with rheumatoid arthritis (RA) and concomitant diabetes mellitus, who showed a marked decrease of fructosamine levels after initiating therapy with adalimumab, a TNF{alpha}-blocking agent, for active RA. This finding may implicate that TNF{alpha} blockade causes better glycaemic control in RA patients with concomitant diabetes, possibly by improving insulin resistance.




This article has been cited by other articles:


Home page
 Diabetes CareHome page
L. Mastrandrea, J. Yu, T. Behrens, J. Buchlis, C. Albini, S. Fourtner, and T. Quattrin
Etanercept Treatment in Children With New-Onset Type 1 Diabetes: Pilot Randomized, Placebo-Controlled, Double-Blind Study: Response to Peters
Diabetes Care, December 1, 2009; 32(12): e154 - e154.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
V P van Halm, M J L Peters, A E Voskuyl, M Boers, W F Lems, M Visser, C D A Stehouwer, A M W Spijkerman, J M Dekker, G Nijpels, et al.
Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation
Ann Rheum Dis, September 1, 2009; 68(9): 1395 - 1400.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
L. Mastrandrea, J. Yu, T. Behrens, J. Buchlis, C. Albini, S. Fourtner, and T. Quattrin
Etanercept Treatment in Children With New-Onset Type 1 Diabetes: Pilot randomized, placebo-controlled, double-blind study
Diabetes Care, July 1, 2009; 32(7): 1244 - 1249.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 European Society of Endocrinology.